Contents

Executive Summary

Empagliflozin was presented to the medical world **as a breakthrough**: **a diabetes drug associated with a striking 38% reduction in cardiovascular death in the EMPA-REG OUTCOME trial**.

That claim mattered enormously. It helped elevate the drug into a major clinical and commercial asset, shaped professional enthusiasm, and contributed to its later stabilization within mainstream treatment narratives. This report examines whether that narrative ***became cleaner, stronger, and more certain than the underlying record justified.***

The central finding is **not** that empagliflozin lacks value. Later evidence **supports meaningful benefits, particularly in heart failure and kidney disease**.

The central finding is narrower: **the original mortality story appears more fragile than the dominant narrative often suggested**. The report identifies multiple points of tension around EMPA-REG, including the unusually rapid timing of the claimed benefit, uncertainty around the classification of key deaths, regional inconsistency, stroke-related cardiovascular disease, and the absence of a convincing dose-response pattern. Taken together, these issues do not automatically invalidate the trial, but they do weaken the impression of a clean, decisive mortality miracle.

The report also finds that the narrative was not stabilized mainly by *detached external confirmation*. Much of the later literature that defended, extended, or biologically explained the original claim emerged from **a sponsor-linked interpretive ecosystem**. Mechanistic explanations, post hoc reframings, and supportive analyses often helped smooth over unresolved tensions rather than decisively settle them. The report's authorship audit makes that pattern visible: across the core papers used to stabilize the empagliflozin story, **financially aligned authors account for 83% to 100% of named authors in the sample shown.**

Regulators occupy an especially important position in this story. They are not pharmaceutical companies, and this report does not treat them as such. But regulators often make decisions on the basis of evidence packages assembled by sponsors, under conditions of uncertainty, time pressure, and practical constraint. In the empagliflozin case, the report argues that regulatory acceptance and independent clinical certainty were not the same thing. Once a narrow and uneasy approval was granted, *the wider medical system had a strong tendency to interpret that decision as stronger confirmation than it may actually have represented*.

Introduction and Disclaimer

Executive Mission and Strategic Alignment

Ansilo Data Labs (ADL) is the analytical intelligence division of Ansilo Global Enterprises. Its role is to produce **evidence-led reports** and decision tools that help readers navigate complex scientific, regulatory, and commercial landscapes with greater **clarity** and independence.

ADL is built on a simple premise: in healthcare and pharmaceuticals, important decisions are often shaped not only by what is **known**, but by what is **emphasized**, **omitted**, **delayed**, or framed in ways that **overstate certainty**. Our work is designed to examine these points of tension carefully, drawing together fragmented public evidence into structured, usable analysis.



Sources: 1. Horton R. Offline: What is medicine's 5 sigma? Lancet. 2015;385(9976):1380. doi:10.1016/S0140-6736(15)60696-1. 2. Angell M. Drug companies & doctors: a story of corruption. N Y Rev Books. 2009 Jan 15;56(1).

Figure 1: Published data requires careful evaluation

Published literature should not automatically be treated as the full evidentiary picture. The visible scientific record may reflect not only what was discovered, but also what was emphasized, published, repeated, and absorbed into mainstream interpretation.

At the heart of ADL is the belief that **decision quality** depends on **evidentiary quality**. When published data is **incomplete**, **selectively presented**, or interpreted through **conflicted incentives**, clinicians, patients, investors, and policymakers may inherit more confidence than the evidence can cleanly support.



Figure 2: The Anatomy of Influence

Clinical narratives are s ped by primary data alone. They are also influenced by the institutions and pathway hich evidence is presented, interpreted, and legitimized.

ADL exists to reduce these dentiary asymmetries. This is both a **practical** and **ethical** undertaking. In the health sector, **distorted interpretation** does not remain abstract; it can shape **prescribing**, **regulation**, **standards of care**, **capital allocation**, and ultimately **patient outcomes**.

Why the EMPA-REG result mattered so much

To understand why EMPA-REG created such excitement, you must understand the background. For decades, medicine faced a grim reality: **nearly two-thirds of people with diabetes** died from cardiovascular complications.[5] Strokes, myocardial infarctions, and other vascular events drove enormous morbidity and mortality.

And despite all the focus on glucose control, lowering blood sugar alone **did not reliably translate into fewer cardiovascular deaths**.[6] Correcting blood sugar did not stop the heart attacks from happening.



Figure 14: Controlling blood sugar alone does not improve CV outcomes

That was the frustration. Doctors could improve glucose numbers, yet patients still died from heart disease. Trials targeting hyperglycemia repeatedly failed to demonstrate the kind of cardiovascular mortality benefit clinicians wanted.

So when EMPA-REG appeared to show a dramatic reduction in cardiovascular death, **the response was explosive.** The room was electrified.[1][3] A thirty-eight percent reduction is a massive number in literally any field of medicine. But in this specific context, diabetes and heart disease, it was just unheard of.[1][2]

It was described as a **breakthrough, a game changer,** even **the holy grail of diabetes care.**



Figure 20: CV benefits disappears when 'mystery deaths' removed.

And yet those deaths were still counted as cardiovascular deaths under the trial's adjudication framework.[4][10] Because this specific trial was focused on tracking cardiovascular outcomes, the researchers just presumed that these mystery deaths were cardiovascular in origin. They just lumped them into the final tally. The uncomfortable truth is that when these mystery deaths were removed, the P value spikes, indicating that any remaining difference between the drug and the placebo is essentially indistinguishable from random noise.[4][10]

That matters enormously. Because when regulators examined what happened after removing those uncertain cases from the analysis, the dramatic mortality advantage was no longer persuasive.[10] The signal weakened substantially, and the apparent miracle looked far less secure. **This is one of the most serious concerns in the whole trial.** If a major headline benefit depends heavily on deaths whose causes were never clearly established, the result becomes much more fragile than the public narrative suggests.

3) The geographic anomaly

Then there is the regional inconsistency.

If a drug is truly acting through a robust and universal biological mechanism, you would expect broadly consistent benefit across human populations. But in EMPA-REG, the data were not evenly convincing across regions. [4]

Featured report: APRIL 2026:
EMPAGLIFLOZIN

Multi-user Licencees receive early notification of new publications